Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Announces the Appointment of K. Scott Bland as Vice President of Sales at Berkeley HeartLab
FOR IMMEDIATE RELEASE

Alameda, CA - January 14, 2009

Celera (NASDAQ:CRA) today announced the appointment of K. Scott Bland to the new position of Vice President of Sales at its Berkeley HeartLab, or BHL, subsidiary. The appointment is effective immediately and Mr. Bland will report to Chris Hall, Chief Business Officer of BHL.

Mr. Bland has been a regional director of sales at BHL, providing oversight to sales activities in the southeast of the United States for the last two years. Prior to joining BHL, Mr. Bland was a regional business advisor for Allergan Pharmaceuticals, and he also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott. Mr. Bland received his B.S. and his M.B.A. degrees from The Citadel in Charleston, South Carolina.

“Scott adds a tremendous wealth of experience in cardiovascular disease management to our team at Berkeley HeartLab,” said Chris Hall, Chief Business Officer of Berkeley HeartLab. "We’ve experienced substantial growth and expansion at BHL, and as a result there’s a need to strengthen our commercial infrastructure. This new position goes a long way toward achieving this, and with a strong customer focus and a deep knowledge of the cardiovascular disease industry, we think Scott is well positioned to lead our sales efforts to deliver on our vision of personalizing disease management.”

About Celera
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.

Copyright© 2009. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U.S. and/or certain other countries.

Contact
David Speechly, Ph.D.
tel.: 510.749.1853
email: david.speechly@celera.com


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.